Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals' SEC filings reveal the financial and operational details behind its RNA interference therapeutic development programs. For a clinical-stage biopharmaceutical company with multiple programs spanning rare diseases and cardiometabolic conditions, these regulatory documents contain insights not available through press releases or presentations.
The company's 10-K annual reports break down research and development expenses by therapeutic area, showing which programs receive the most investment. These filings detail clinical trial timelines, regulatory interactions with the FDA and international agencies, and the status of patent applications protecting individual drug candidates. For investors tracking Alnylam's pipeline, the 10-K provides granular disclosure about each program's stage of development, target indications, and potential market opportunities. Manufacturing capacity, supply chain arrangements, and production facility investments also receive detailed treatment in annual filings.
Quarterly 10-Q reports track clinical trial enrollment progress, interim data readouts, and changes to development timelines between annual filings. These documents reveal shifts in resource allocation as programs advance or face setbacks, and they disclose new collaborative agreements or modifications to existing partnerships. For a company advancing multiple RNAi therapeutics simultaneously, the 10-Q shows which programs are progressing and which face delays.
Form 4 insider transaction filings reveal when executives and directors buy or sell Alnylam shares. These transactions sometimes precede material announcements about clinical data or regulatory decisions, making them relevant for investors monitoring company insiders' confidence levels. The 8-K material event reports capture significant developments like clinical trial results, regulatory submissions, debt offerings, and leadership changes as they occur.
AI-powered summaries on this page simplify these complex biotechnology disclosures, highlighting key pipeline updates, financial metrics, and regulatory milestones without requiring hours of manual document review.
Alnylam Pharmaceuticals, Inc. director Stuart A. Arbuckle filed an initial insider ownership report. This Form 3 indicates that, as of the event date of 01/05/2026, he holds no securities beneficially owned in Alnylam. The filing confirms his role as a director and that the report is filed by one reporting person.
The document also includes a power of attorney, under which Brett Budzinski signed on Arbuckle's behalf. This filing is primarily administrative, establishing Arbuckle’s status as an insider without disclosing any equity ownership or transactions.
Alnylam Pharmaceuticals executive Kevin Fitzgerald, CSO & EVP, Head of Research, reported an insider transaction in ALNY common stock. On 11/17/2025, he exercised a stock option for 8,161 shares at an exercise price of $119.13 per share and acquired the underlying common stock.
That same day, he reported multiple open-market sales of ALNY common stock in separate small lots, including 8,168 shares at $449 per share and additional sales at weighted average prices spanning from $451.41 to $463.46 per share, each based on multiple individual trades. After these transactions, he reported beneficial ownership of 24,999 shares directly, 537 shares indirectly through a managed account, and 839 derivative securities remaining from the option award. The filing notes that these trades were made under a Rule 10b5-1(c) trading plan adopted on August 14, 2025.
Alnylam Pharmaceuticals reported strong Q3 2025 results, with total revenue of
The company delivered income from operations of
Within franchises, TTR therapies (AMVUTTRA and ONPATTRO) generated
Alnylam Pharmaceuticals (ALNY) announced its financial results for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 with additional details.
The information is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.
Alnylam Pharmaceuticals (ALNY) officer Bryan Supran reported acquiring 13,026 shares of common stock via a restricted stock unit (RSU) grant on 10/01/2025. Each RSU represents the right to receive one share. The RSUs vest over three years, with one third vesting on each of the first, second, and third anniversaries of the grant date, contingent on continued service.
Following the reported transaction, 13,026 shares were beneficially owned on a direct basis.
Jeffrey V. Poulton, EVP and Chief Financial Officer of Alnylam Pharmaceuticals (ALNY), reported equity changes tied to performance-based stock units (PSUs) that vested following corporate milestones. On 10/01/2025 the reporting person received 3,108 shares from a 2/24/2021 PSU tranche and 4,644 shares from a 3/01/2024 PSU tranche after the issuer publicly reported initiation of a Phase 3 clinical study in a prevalent indication, as determined by the People, Culture and Compensation Committee.
The company automatically sold 3,821 shares on 10/02/2025 under a mandatory sell-to-cover provision to satisfy statutory tax withholding, at weighted-average prices ranging roughly from $446.19 to $456.09 across multiple transactions. After these transactions the reporting person beneficially owned 54,052 shares directly and 57 shares indirectly via a managed account; 57 additional shares were acquired under the issuer 401(k) matching program.
Alnylam Pharmaceuticals (ALNY) CEO Yvonne Greenstreet reported PSU-related share activity. On 10/01/2025, she acquired 3,860 and 14,252 shares at $0 upon PSU vesting tied to the initiation of a Phase 3 clinical study, as determined by the PC&C Committee. On 10/02/2025, the Company executed sell-to-cover transactions to satisfy tax withholding, with multiple weighted-average sales ranging from $446.53 to $457.64. Following these transactions, she held 65,409 shares directly and 407 shares indirectly by a managed account.
Alnylam Pharmaceuticals (ALNY) executive Tolga Tanguler, EVP and Chief Commercial Officer, reported equity activity on a Form 4. On 10/01/2025, 2,851 common shares were acquired at $0.00 upon vesting of performance-based stock units tied to the initiation of a Phase 3 clinical study, as determined by the Board’s People, Culture and Compensation Committee.
On 10/02/2025, shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy tax withholding, executed in multiple trades with weighted average prices ranging from $446.19 to $457.64. Following these transactions, the reporting person beneficially owned 27,438 shares directly.
Alnylam Pharmaceuticals (ALNY) EVP Chief R&D Pushkal Garg reported PSU vesting and related share sales. On 10/01/2025, he acquired 3,108 and 2,851 common shares at $0.00 upon vesting tied to the company publicly reporting the initiation of Phase 3 clinical studies, as determined by the Board’s PC&C Committee.
On 10/02/2025, shares were sold automatically to cover taxes from the PSU settlements at disclosed weighted average prices by tranche; additional sales on 10/03/2025 were made under a Rule 10b5‑1(c) trading plan adopted on 09/11/2024. After these transactions, direct holdings were 20,221 shares, with 431 held via a managed account and 250 held in a trust.
Alnylam Pharmaceuticals reported a material event on an Form 8-K that discloses a Credit Agreement dated September 30, 2025 among Alnylam, the lenders party to the agreement, and Bank of America, N.A. acting as Administrative Agent. The filing references an interactive cover page data file embedded within the Inline XBRL document and is signed by Jeffrey V. Poulton, Executive Vice President and Chief Financial Officer. No loan amounts, interest terms, covenants, maturity dates, or other economic details are included in the provided text.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
